• Publications
  • Influence
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Aims The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening andExpand
  • 1,436
  • 96
  • PDF
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
BACKGROUND Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patientsExpand
  • 1,543
  • 51
  • PDF
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This EuropeanExpand
  • 716
  • 28
  • PDF
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
BACKGROUND Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on theExpand
  • 838
  • 23
  • PDF
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial
Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) andExpand
  • 437
  • 20
  • PDF
Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation.
OBJECTIVES We sought to evaluate whether increased sympathetic outflow may interfere with flow-mediated dilation (FMD). BACKGROUND Endothelial function, assessed as FMD, is frequently used as anExpand
  • 326
  • 18
A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200
Although the atheroprotective role of HDL cholesterol (HDL-c) is well documented, effective therapeutics to selectively increase plasma HDL-c levels are not yet available. Recent progress inExpand
  • 233
  • 17
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic,Expand
  • 319
  • 16
  • PDF
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
OBJECTIVES We assessed relations of low-density lipoprotein (LDL) particle number (LDL-P) and LDL particle size as measured by nuclear magnetic resonance spectroscopy with LDL cholesterol (LDL-C) andExpand
  • 241
  • 15
  • PDF
Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia
Patients with aneurysmal subarachnoid hemorrhage (SAH) who experience delayed cerebral ischemia (DCI) have an increased risk of poor outcome. Delayed cerebral ischemia is considered to be caused byExpand
  • 225
  • 15
  • PDF
...
1
2
3
4
5
...